The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenue | - | - | 260 | - |
| Cost of revenues | - | - | 112 | - |
| Personnel-related expenses and board fees | - | - | 3,329 | - |
| Professional fees, legal, and outside services | - | - | 3,094 | - |
| Facilities and insurance | - | - | -837 | - |
| Laboratory supplies and expenses | - | - | 943 | - |
| Marketing and advertising | - | - | 97 | - |
| Travel and entertainment | - | - | 185 | - |
| Other segment items | - | - | -98 | - |
| Segment loss from operations | - | -8,666 | -6,565 | - |
| Depreciation and amortization expenses | - | 563 | 584 | - |
| Stock-based compensation | - | 721 | 521 | - |
| Change in fair value of contingent consideration | -5,918 | -1,115 | 3,378 | - |
| Impairment losses | - | 14,600 | - | - |
| Impairment loss on held for sale assets | - | 0 | 0 | - |
| Loss from operations | - | - | -11,048 | - |
| Interest expense | -23 | -26 | -29 | - |
| Other income, net | 146 | 506 | 223 | - |
| Impairment losses | - | 14,600 | - | - |
| Income taxes | - | 0 | 0 | - |
| Impairment loss on held for sale assets | - | 0 | 0 | 0 |
| Net loss | -4,290 | -22,955 | -10,854 | -16,413 |
| Depreciation and amortization expense | 631 | 563 | 584 | 1,043 |
| Amortization of intangible assets | 0 | 0 | 0 | 7 |
| Stock-based compensation | 615 | 721 | 521 | 977 |
| Equity compensation for bonus awards and consulting services | 32 | 38 | 38 | 88 |
| Change in fair value of contingent consideration | -5,918 | -1,115 | 3,378 | 3,683 |
| Unrealized foreign currency (gains) losses | 5 | -15 | -170 | - |
| Accounts receivable | -971 | 870 | -254 | -1,101 |
| Inventories | -64 | -25 | -222 | 283 |
| Prepaid expenses and other assets | -449 | 102 | -65 | 189 |
| Accounts payable and accrued liabilities | -105 | 3,555 | 1,177 | -2,086 |
| Operating lease assets and liabilities | -83 | -20 | -57 | -65 |
| Net cash used in operating activities | -7,639 | -5,545 | -4,502 | -12,137 |
| Proceeds from sale of equipment | - | 0 | - | - |
| Machinery and equipment purchases, and construction in progress | 613 | 1,479 | 1,050 | 656 |
| Net cash used in investing activities | -613 | -1,479 | -1,050 | -656 |
| Proceeds from sale of common shares | 26,024 | 0 | 0 | 29,143 |
| Financing costs to issue common shares | 1,183 | 0 | 0 | 487 |
| Proceeds from sale of common shares under at-the-market transactions | - | 0 | 0 | - |
| Financing costs for at-the-market sales | - | 0 | 0 | - |
| Redemption of series a redeemable convertible preferred shares | - | 0 | 0 | 0 |
| Contingent consideration liability payments | - | 2 | - | - |
| Taxes paid related to net share settlement of stock-based awards | - | 72 | - | - |
| Repayment of financing lease obligations | 143 | 178 | 120 | 212 |
| Net provided by financing activities | 24,698 | -252 | -120 | 28,444 |
| Effect of exchange rate changes on cash and cash equivalents | -10 | -15 | -105 | - |
| Net change in cash, cash equivalents and restricted cash | 16,436 | -7,291 | -5,777 | 15,651 |
| Cash, cash equivalents and restricted cash, beginning | 12,919 | -9,874 | 10,336 | - |
| Cash, cash equivalents and restricted cash, ending | 29,355 | -7,291 | 20,210 | - |
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)